ARS starts a Phase III comparative open-label study in 120 patients with Pyelonephritis expected to be enrolled at six Russian sites. The project is financed by the leading distributor and promoter of antibacterial and antituberculosis drugs in the Russian hospital market. ARS will be also responsible for the following drug registration in Russia.